Featured Article

Update on ICH E6 (R2) Guideline for GCP

The ICH E6 R2 Addendum is starting to have a significant, positive impact on clinical trial design – offering a real opportunity to inject efficiencies into clinical research and development.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Press Release
CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM
  • New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing...
Read More
Blog
The Hidden Inspection Risk in Your Medical and Safety Review Workflow
  • You have just been told an inspection is coming. Your team’s first reaction is not to...
Read More
Blog
Why Medical and Safety Review Is One of the Last Manual Workflows in Clinical Trials
  • It is Tuesday morning. You have a data cut from last night, three studies to review...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI